Key result
Simvastatin significantly slows angiographic CAD progression versus placebo, reducing minimum lumen diameter loss by ~80%.
Why the study?
Higher dosages of simvastatin may have a greater effect and require shorter treatment time to reduce progression of coronary artery disease, but this was uncertain.
Does simvastatin 40 mg daily reduce the progression of coronary artery disease in men with documented coronary artery disease and hypercholesterolaemia?
RCT (n=254)
double-blind
randomized
Yes
Does simvastatin 40 mg daily reduce the progression of coronary artery disease in men with documented coronary artery disease and hypercholesterolaemia?
Absolute Event Rate: 0.2% vs 0.58%
p-value: p=0.02
Simvastatin 40 mg daily significantly slows the angiographic progression of coronary artery disease in men with hypercholesterolemia over an average of 2.3 years.
No takes yet. Share an insight, caveat, or question.
Supports statin use to slow CAD progression in hypercholesterolemic men; confirms LDL-lowering benefits on atherosclerosis progression.
Bestehorn et al. (1997) conducted an RCT in coronary artery disease and hypercholesterolaemia (n=254). simvastatin vs. placebo was evaluated on global change score and per patient mean change of minimum lumen diameter (p=0.02). Simvastatin significantly slowed coronary artery disease progression compared to placebo, with a mean global change score of +0.20 vs +0.58 (P=0.02) and minimum lumen diameter change of -0.02 vs -0.10 mm (P=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: